Roche announced two Phase 3 successes for its BTK inhibitor fenebrutinib in different multiple sclerosis populations, clearing registrational endpoints after a wave of earlier failures in the class. The program showed non‑inferiority to incumbent therapies in one trial and met primary outcomes in the other, according to company releases. The results mark a notable turnaround for BTK inhibitors in neuroimmunology, where safety and efficacy concerns have hampered progress. Roche’s dual wins position fenebrutinib as a late‑stage entrant for both relapsing and progressive MS indications, and the company will now pursue regulatory submissions and broader outcome datasets. Clinicians and investors will watch detailed safety data and subgroup analyses closely; success in two distinct registrational studies strengthens Roche’s claim that BTK modulation can be effective across MS subtypes.